While 2013 Annual Report Includes Gianvi And Ocella Drug Injury Cases, The Only Mention Of Beyaz And Safyral Legal Cases Is Regarding Patent Disputes
(Posted by Tom Lamb at DrugInjuryWatch.com)
The YAZ / Yasmin litigation which began back in 2009 is going on its fifth year. Here are the latest numbers made available by the defendant drug company about claims, lawsuits, and settlements.
From the Bayer 2013 Annual Report which was issued recently:
- As of February 10, 2014, the number of claimants in the pending lawsuits and claims in the United States totaled about 4,600 (excluding claims already settled). Claimants allege that they have suffered personal injuries, some of them fatal, from the use of Bayer’s drospirenone-containing oral contraceptive products such as Yasmin™ and / or YAZ™ or from the use of Ocella™ and / or Gianvi™....
- As of February 10, 2014, Bayer had reached agreements, without admission of liability, to settle the claims of approximately 8,250 claimants in the U.S. for a total amount of about US$1.69 billion. Bayer has only been settling claims in the U.S. for venous clot injuries (deep vein thrombosis or pulmonary embolism)....
- Such injuries are alleged by about 1,950 of the pending unsettled claimants. Bayer will continue to consider the option of settling individual claims for venous clot injuries in the U.S. on a case-by-case basis.
- As of February 10, 2014, about 8,800 plaintiffs had decided to participate in the [$24 million dollar gallbladder cases] settlement, which represents more than 95% (90% participation required) of the eligible plaintiffs, so the settlement will go forward.
- Additional lawsuits are anticipated.
Lastly, on a different but related subject, the Bayer 2013 Annual Report includes this statement (without any elaboration or explanation): "We are not currently pursuing approval for the oral contraceptive YAZ™ Flex Plus in the United States."
Compare this current position to what was stated in the Bayer Stockholders’ Newsletter for the 3rd Quarter 2013, that among "[t]he most important drug candidates in the approval process [as of October 17, 2013]... YAZ™ Flex Plus U.S.A.; oral contraception with flexible dosage regimen and folic acid supplementation."
We will continue to monitor the YAZ / Yasmin litigation, including the status of filed and unfiled Beyaz and Safyral cases involving blood clot side effects like deep vein thrombosis (DVT) and pulmonary embolism (PE).